Impaired Prothrombin Consumption in Bernard-Soulier Syndrome Is Corrected In Vitro by Human Factor VIII

S Bellucci; J P Girma; M Lozano; D Meyer; J P Caen

doi:10.1055/s-0038-1655972

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 77(02): 383-386
DOI: 10.1055/s-0038-1655972

Original Article

Schattauer GmbH Stuttgart

Impaired Prothrombin Consumption in Bernard-Soulier Syndrome Is Corrected In Vitro by Human Factor VIII

S Bellucci

¹Laboratory of Hematology and Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris

,

J P Girma

²Inserm U.143. Hôpital de Bicêtre, Le Kremlin-Bicêtre, France

,

M Lozano

³Haemotherapy and Haemostasis Department, Hospital Clinic, Barcelona, Spain

,

D Meyer

²Inserm U.143. Hôpital de Bicêtre, Le Kremlin-Bicêtre, France

,

J P Caen

¹Laboratory of Hematology and Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris

› Author Affiliations

Abstract

PDF Download

Summary

The Bernard-Soulier syndrome (BSS) is characterized by thrombocytopenia with giant platelets, a prolonged bleeding time with defective platelet adhesion to the subendothelium related to a defect in platelet membrane glycoprotein lb (GPIb) and a decreased prothrombin consumption. The mechanism of the latter abnormality remains unknown. In this study, we showed that this defect was corrected by the addition of purified human factor VIII (FVIII) to blood from four patients with BSS. The correction of prothrombin consumption was almost complete at concentrations between 1.5 and 3 IU/ml of FVIII procoagulant activity (VIII.'C) and partially abolished by a monoclonal antibody which neutralizes VIII:C. This correction was specific for FVIII and was not observed after addition of purified human FIX. It was obtained, in the same magnitude range, with FVIII complexed to von Willebrand factor (vWF) but not with free vWF. These data provide a new insight into the knowledge of the physiological interaction between the platelet membrane and the vWF-FVIII complex facilitating plasma coagulation activation and may lead to helpful therapeutic advances.

PDF (316 kb)

References

References
1 Bernard J, Soulier JP. Sur une nouvelle variétéde dystrophie thrombocytaire hémorragipare congénitale. Sem Hop Paris 1948; 97: 3217-3123
2 Nurden AT, Caen JP. Specific roles for surface glycoproteins in platelet function. Nature 1975; 255: 720-722
3 Jamieson GA, Okumura T, Fishback B, Johnson MM, Egan JJ, Weiss HJ. Platelet membrane glycoproteins in thrombasthenia, Bemard-Soulier syndrome and storage pool disease. J Lab Clin Med 1979; 93: 652-660
4 Clemetson KJ, Mc GregorJL, James E, Dechavanne M, Luscher EF. Characterization of the platelet membrane glycoprotein abnormality in Bemard-Soulier syndrome and comparison with normal by surface-labeling techniques and high resolution two-dimensional gel electrophoresis. J Clin Invest 1982; 70: 304-311
5 Caen J, Bellucci S. The defective prothrombin consumption in BemardSoulier syndrome. Hypotheses from 1948 to 1982. Blood Cells 1983; 09: 389-399
6 Walsh PN, Mills DCB, Pareti FI, Stewart GJ, Macfarlane DE, Johnson MM, Egan JJ. Hereditary giant platelet syndrome:absence of collagen-induced coagulant activity and deficiency of factor XI binding to platelets. Brit J Haematol 1975; 29: 639-655
7 Caen J, Lévy-Toledano S, Sultan Y, Bernard J. La dystrophie thrombocytaire hemorragipare (Interaction des plaquettes et du facteur Willebrand). Nouv Rev Fr Hematol 1973; 13: 595-602
8 Bevers EM, Comfurius P, Nieuwenhuis K, Lévy-Toledano S, Einouf J, Bellucci S, Caen JP, Zwaal RFA. Platelet prothrombin converting activity in hereditary disorders of platelet function. Brit J Hematol 1986; 63: 335-345
9 Bernard J, Caen JP, Maroteaux P. La dystrophie thrombocytaire hémorragipare congénitale. Revue d’Hématologie 1957; 12: 222-249
10 Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G, Lévy-Toledano S, Sultan Y, Valensi F, Bernard J. Bernard-Soulier syndrome, a new platelet glycoprotein abnormality:its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 1976; 87: 586-596
11 Hourdille P, Pico M, Jandrot-Perrus M, Lacaze D, Lozano M, Nurden AT. Studies on the megakaryocytes of a patient with the Bemard-Soulier syndrome. Brit J Haematol 1990; 76: 521-530
12 Simsek S, Noris P, Lozano M, Pico M, von dem BorneAEGKr, Ribera A, Gallardo D. Cys209 Ser mutation in the platelet membrane glycoprotein Ibαgene is associated with Bemard-Soulier Syndrome. Brit J Haematol 1994; 88: 839-844
13 Quick AJ, Favre-Gilly JE. The prothrombin consumption test. Blood 1949; 4: 1281-1286
14 Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand Factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 1990; 64: 326-332
15 Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to Factor VIII. Blood 1989; 74: 1591-1599
16 Meyer D, Zimmerman TS, Obert B, Edgington TS. Hybridoma antibodies to human von Willebrand Factor I. Characterization of seven clones. Brit J Haematol 1984; 57: 597-608
17 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283
18 Van DieijenG, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor Villa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442
19 Perret B, Lévy-Toledano S, Plantavid M, Bredoux R, Chap H, Tobelem G, Douste-Blazy L, Caen JP. Abnormal phospholipid organization in BemardSoulier platelets. Thromb Res 1983; 31: 529-537